Souhaitez-vous accéder aux communiqués récents ?

Cosmos Health inaugurates state-of-the-art capsule production line and secures new 5-year contract manufacturing agreement for 385,000 units

Cosmos Health acquires international patent application WO2025108566A1 and expands nanotechnology initiatives.

Cosmos Health launches Oliv18™, a USDA and EU certified whole olive polyphenol supplement targeting cardiovascular and antioxidant categories.

Sky Premium Life is now available for shipment across all 27 European Union Member States through Skroutz.

Cosmos Health identifies approximately $20 million in non-core assets available for monetization to accelerate growth and unlock shareholder value.

Cosmos Health provides balance sheet update and notes no known business reason for reason for recent share price decline. Reaffirms growth outlook.

Cosmos Health enters the animal health market, extending the C-Scrub brand into the veterinary space following successful European standard testing.

Cosmos Health Releases 2026–2029 Guidance: Targeting $200M Revenue, $71M Gross Profit, and $44M Adjusted EBITDA by 2029.

Cosmos Health Provides Update; Evaluates Options to Address Valuation Disconnect; Will Issue Updated Guidance Following FY 2025 Results

Cosmos Health purchases $600,000 worth of Bitcoin, bringing total investment in digital assets to $3.1 million.